Investment Portfolio
We have the expertise. We have the track record. We put Ontario First. FACIT actively manages its diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development. Our active portfolio consists of both early-stage assets and more than 35 companies advancing oncology therapeutics, medical technologies, diagnostics and informatics/AI. Our portfolio has raised more than $1.6B from global investors in follow-on financing.
Investment Philosophy
FACIT strategically invests in oncology breakthroughs and companies arising from Ontario’s outstanding innovation ecosystem. By fostering a culture of entrepreneurship and commitment to the value of commercialization, we support inventors and researchers in capitalizing on their cancer related innovations.
Why invest with FACIT
Our partners gain access to outstanding science and oncology innovations in a variety of areas such as new technology, therapeutics, imaging and diagnostics. Through our expertise in identifying and commercializing the most promising assets, we help investors reduce the risk of their early-stage involvement.
SEARCH FILTERS:
Innovation Type
Cancer Type
Current Funding Stage
FACIT Fund
Virano Therapeutics
DTPx Therapeutics (UHN)
Point Surgical Inc.
OICR
OICR
Hyivy Health
HDAX Therapeutics
OICR
Air Microfluidic Systems Inc.
Tenomix
Sunnybrook Research Institute
doctalk
Bridge7 Oncology
Replica Analytics (Aetion)
Multimagnetics Inc.
University of Toronto
Radiant Biotherapeutics
cTRL Therapeutics
Xpan Inc
OICR
Sunnybrook Research Institute
University of Toronto (Perturba)
Polumiros
Talon Pharmaceuticals
Notch Therapeutics
OICR
QurCan Therapeutics (formerly Nanology Labs)
16-Bit
DNAstack
Dalriada Therapeutics
KA Imaging
Radialis Medical
Ottawa Hospital Research Institute
OICR
Propellon Therapeutics Inc. (Triphase Accelerator)
Pattern Pharma (formerly Realist Pharma)
Queen’s University
Fusion Pharmaceuticals Inc
Novera Therapeutics Inc.
FocusOnCare
Capnostics
Sunnybrook Research Institute
OICR
Sunnybrook Research Institute
Ziliomics
Sunnybrook Research Institute
OICR
Turnstone Biologics Inc
Fluorinov Pharma (Trillium)
OICR (Cellax)
XLV Diagnostics
Privacy Analytics (IQVIA)
Arrayus Technologies (formerly Harmonic Medical)
McMaster University
Triphase Accelerator Corporation
Kapplex
Xagenic
DLVR Therapeutics
University of Toronto (Receptor-OncoTek)
DVS Sciences (Fluidigm/Standard BioTools)
UHN (TorCell Therapeutics)
UHN
Sunnybrook Research Institute
UHN
ArcticDx
Profound Medical
FACIT has been nationally recognized by industry peers with a Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA). The award acknowledges FACIT’s strategic commercialization investments that have positioned our portfolio companies to deliver meaningful impacts on Ontario’s life sciences industry. FACIT is the first and only Ontario life science commercialization organization to achieve this recognition.